Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 360

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 360
---
                                                                          
 management and Orrick, Herrington & Sutcliffe, concerning the likelihood that regulatory approvals and clearances necessary to consummate the Mergers would be obtained. |

| • |     | Kineta’s Liquidation Prospects. In connection with the evaluation of the Mergers by the Kineta                                                                                                                                                     
 Board of Directors, Kineta management prepared an analysis with respect to the estimated value of the liquidation or dissolution of Kineta as a potential alternative to the Mergers, including for such purposes Kineta’s estimated cash position 
 at the time of the potential dissolution or liquidation, Kineta’s estimated expenses in connection with any such liquidation or dissolution, and the amount of cash available to be distributed to Kineta’s stockholders in connection with any    
 such proposed future dissolution or liquidation. The Kineta Board of Directors undertook a comprehensive and thorough process of reviewing and analyzing potential strategic alternatives and merger partner candidates and                        |

226

| the Kineta Board of Directors concluded that no alternatives to the Mergers (including a liquidation or dissolution of Kineta to distribute any available cash) were reasonably likely to create 
 greater value to the Kineta stockholders.                                                                                                                                                        |

| • |     | Consideration of Strategic Alternatives. The Kineta Board of Directors took into account its review of                                                                                                                                                   
 strategic alternatives and opportunities available to Kineta, including the risks and benefits of continuing to operate as an independent public company in its current configuration, pursuing acquisitions or licensing transactions as an independent 
 public company and pursuing alternative strategic transactions, including the discussions that Kineta’s management, Kineta’s Representatives and the Kineta Board of Directors had in previous years with other potential strategic transaction          
 candidates.                                                                                                                                                                                                                                              |

| • |     | Terms of the Agreements. The review by the Kineta Board of Directors with its advisors of the structure of                                                                                                                                          
 the Transactions and the financial and other terms of the Merger Agreement, the HCRX Asset Purchase Agreement, the Pacira Agreement, and the GigaGen Agreement, including the parties’ representations, warranties and covenants, the conditions to 
 their respective obligations to complete the Transactions and the termination provisions as well as the likelihood of consummation of the Transactions and the evaluation of the Kineta Board of Directors of the likely time period necessary to   
 complete the Transactions. The Kineta Board of Directors also considered the following specific aspects:                                                                                                                                            |

With respect to the Merger Agreement:

| • |     | the limited number of closing conditions included in